Ten Stocks Trending on Discord for Monday August 22, 2022: AMC, GBNH, BBBY, NEPT, SMMT, AVYA, ANPC, APRN, DNAA, KRBP
$AMC
$ANPC
$APRN
$AVYA
Movies/Entertainment
Consumer Discretionary
Medical Specialities
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/4/2024 | $32.00 | Mkt Outperform | JMP Securities | |
| 9/27/2024 | $19.00 → $23.00 | Buy → Neutral | Citigroup | |
| 8/12/2024 | $16.00 | Buy | H.C. Wainwright | |
| 5/7/2024 | $7.00 | Buy | Citigroup | |
| 3/26/2024 | $8.00 | Buy | Stifel | |
| 2/29/2024 | $12.00 → $8.00 | Neutral | B. Riley Securities | |
| 9/26/2023 | $15.50 → $4.75 | Sell | Citigroup | |
| 8/24/2023 | $19.00 | Underperform → Neutral | Wedbush |
ZURICH, Sept. 4, 2024 /PRNewswire/ -- Amcor (NYSE:AMCR, ASX: AMC))), a global leader in developing and producing responsible packaging solutions, today announced that its Board of Directors has appointed Peter Konieczny as Chief Executive Officer (CEO). Mr. Konieczny has served as Interim CEO since April 2024. The Board also intends to nominate him as a director for election at the Company's Annual Meeting of Shareholders which is expected to be held in November 2024. Amcor Chairman, Mr. Graeme Liebelt, said, "Peter has demonstrated exceptional leadership in every role he has
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member
Veteran executive joins NCM to lead development and execution of go-to-market strategy to propel next stage of growth across NCM's premium video advertising platform National CineMedia (NASDAQ:NCMI) ("the Company" or "NCM"), the largest cinema advertising platform in the US, today announced the appointment of seasoned media executive and strategist, Catherine Sullivan, as President of Sales, Marketing, and Partnerships, effective May 16, 2024. In this role, Sullivan will oversee the Company's sales and marketing strategy and lead initiatives to continue the momentum of brands returning to the theater to reach sought-after audiences. Sullivan will join the executive leadership team, report
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on November 15, 2024. The options have a ten (10) year term and an exercise price of $18.31 per share, the closing price per share of the Company's common stock as reported by Nasdaq on No
ZURICH, Nov. 13, 2024 /PRNewswire/ -- Amcor (NYSE:AMCR, ASX:AMC)), a global leader in developing and producing responsible packaging solutions has been recognized by the 35th Packaging Innovation Awards (PIA) for its AmPrima® Plus solution for coffee. Sponsored by Dow, this prestigious award recognizes excellence in packaging and encourages advancements in sustainability and performance. The Special Award category, won by Amcor, is dedicated to emerging markets and breaking frontiers in mono-material packaging. Amcor's AmPrima® Plus solution has been commended for its applicat
Airing in select Regal 4DX theaters, the heightened sensory experience is designed to authentically connect the Xfinity brand with highly sought-after moviegoing audiences National CineMedia (NCM), the largest cinema advertising platform in the U.S., in partnership with Comcast's Xfinity, CJ 4DPLEX, and Regal, today announced the first-ever 4DX ad spot in the U.S. In celebration of Universal Pictures' new cinematic event Wicked, the industry-leading brands have teamed up to release the Xfinity short film about the making of Wicked, "Stay Connected to Your Dreams," in 4DX. The spot combines dynamic on-screen visuals with synchronized motion seats and hyper-realistic environmental effects l
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Issuer)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)
SC 13G - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
Exceeds guidance with revenue of $62.4 million Scatter revenue up 35% year-over-year National CineMedia, Inc. (NASDAQ:NCMI) ("the Company" or "NCM"), the managing member and owner of approximately 100% of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising network reaching movie audiences in the U.S., today announced its consolidated results for the fiscal third quarter ended September 26, 2024. "NCM delivered its fourth consecutive quarter of consistent results, achieving $62.4 million in revenue, and demonstrating our strength as the box office continues to accelerate," said Tom Lesinski, CEO of NCM. "We continue to drive meaningful growth in our premium P
Ivonescimab Monotherapy Became First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab Monotherapy in a Phase III Randomized Clinical Trial in NSCLC, HARMONi-2, Reducing Risk of Disease Progression or Death by 49% in First-Line PD-L1 Positive Advanced NSCLC in China Enrollment Completed in Global Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Received Fast Track Designation from FDA; Topline Data Expected in Mid-2025 Summit Intends to Expand HARMONi-3 Global Phase III Trial in 1L Metastatic NSCLC to Include Patients with Tumors of Non-Squamous Histology in Addition to Currently Enrolling Squamous Patients Summit to Initiate Global Phase III HARMONi-7 Trial in 1L PD-L
National CineMedia, Inc. (NASDAQ:NCMI) ("the Company" or "NCM"), the managing member of National CineMedia, LLC ("NCM LLC"), the operator of the largest cinema advertising platform in the U.S., plans to issue its third quarter 2024 earnings results after the market closes on Tuesday, November 5, 2024. A conference call and audio webcast to discuss the results will take place at 5:00 p.m. Eastern Time. The conference call can be accessed by dialing (844) 481-2522 or for international participants (412) 317-0550. Participants should register at least 15 minutes prior to the commencement of the call. Additionally, a live audio webcast will be available to interested parties at www.ncm.com und
JMP Securities initiated coverage of Summit Therapeutics with a rating of Mkt Outperform and set a new price target of $32.00
Citigroup downgraded Summit Therapeutics from Buy to Neutral and set a new price target of $23.00 from $19.00 previously
H.C. Wainwright initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $16.00
8-K - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Filer)
10-Q - Kiromic Biopharma, Inc. (0001792581) (Filer)
10-Q - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Filer)
Wedbush analyst Alicia Reese reiterates AMC Enter Hldgs (NYSE:AMC) with a Neutral and maintains $4 price target.